A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and
endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with
Crohn's disease.